|
Insurance & Litigation
•
|
Tools & Information
•
•
•
|
|
 Back to Reuters Health News Archives
Reuters Health News: 10-17-2004
NEW YORK (Reuters) - Pfizer Inc. PFE.N on Friday said two small clinical trials showed heart bypass surgery patients taking Bextra, an anti-inflammatory in the same class as the recently withdrawn drug Vioxx, had an increased risk of stroke and heart attack.
WASHINGTON (Reuters) - None of Chiron Corp.'s CHIR.O flu vaccine made at a British plant is safe, which means the U.S. flu vaccine supply will be half of what was expected, U.S. health officials said on Friday.
WASHINGTON (Reuters) - The U.S. government ordered antidepressant makers on Friday to put tough warnings on the drugs to alert doctors, parents and patients the medicines increase risks of suicidal behavior among children and teens.
NEW YORK (Reuters Health) - Professionally led support groups may ease anxiety and depression in women who carry gene mutations linked to breast and ovarian cancers, a new study suggests.
NEW YORK (Reuters Health) - The risk of urinary incontinence appears to be one of the things mothers can pass on to their daughters, according to new findings released Friday.
NEW YORK (Reuters Health) - When it comes to walking as part of stroke rehabilitation, faster is better, according to results of a small study.
NEW YORK (Reuters Health) - Most people with uncontrolled asthma can achieve good control over their disease using a combination of the inhaled steroid fluticasone and the long-acting beta-2-agonist salmeterol, according to a study supported by GlaxoSmithKline R&D Limited.
NEW YORK (Reuters Health) - Some people taking the newer class of antidepressants experience excessive sleepiness and fatigue, but this can be prevented with a drug that's used to treat narcolepsy, according to a new report.
NEW YORK (Reuters Health) - Men who take Avodart (dutasteride) to treat an enlarged prostate apparently have a reduced risk for developing prostate cancer, a new study indicates.
NEW YORK (Reuters Health) - Compared with ibuprofen, the use of the lumiracoxib by patients with osteoarthritis is associated with a lower risk of gastric ulcers. The risk is similar to that seen with celecoxib (Celebrex), another COX-2 inhibitor.
|
|
